Researchers Turn to Cloud Computing as Genomic Sequencing Data Threatens to Overwhelm Traditional IT Systems
Seeking Young Scientists for Research in Space
Sounds of Science Podcasts
Tackling the Inevitability of Resistance One Genome at a Time
Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Molecular Diagnostic Reimbursement
Companies are facing significant challenges in gaining provider acceptance and reimbursement for molecular diagnostics, which are the hallmark of personalized medicine. Steven Burrill, CEO of Burrill & Company, even likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.” Some companies are prevailing, however, through strategies that include obtaining a dedicated current procedural terminology (CPT) code, gaining acceptance of diagnostics as a standard of care, and forming partnerships with the pharmaceutical industry. Others are concentrating efforts on developing diagnostics for the ex-U.S. market. How is your company handling this issue?